
OrganiGram Holdings OGI
€ 1.20
0.0%
Geschäftsbericht 2024
hinzugefügt 27.12.2025
OrganiGram Holdings Zahlungsmittel 2011-2026 | OGI
Zahlungsmittel Jährlich OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 24.6 M | 47.6 M | 55.1 M | - | - | - | - | - | - | - |
Alle Zahlen in CAD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 55.1 M | 24.6 M | 42.4 M |
Zahlungsmittel Vierteljährlich OrganiGram Holdings
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 55.4 M | - | - | - | 24.6 M | - | - | - | 47.6 M | - | - | - | 55.1 M | - | - | - | 1.96 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in CAD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 55.4 M | 1.96 M | 36.9 M |
Zahlungsmittel anderer Aktien in der Arzneimittelhersteller
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | ||
|
Assertio Holdings
ASRT
|
10.2 M | $ 19.26 | 0.26 % | $ 123 M | ||
|
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | ||
|
Bausch Health Companies
BHC
|
947 M | $ 5.41 | 1.12 % | $ 1.97 B | ||
|
Aurora Cannabis
ACB
|
138 M | $ 3.44 | - | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
114 M | $ 1.02 | 2.0 % | $ 110 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 3.1 | -2.21 % | $ 43.6 M | ||
|
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M | ||
|
Evolus
EOLS
|
53.8 M | $ 4.16 | 3.23 % | $ 268 M | ||
|
Emergent BioSolutions
EBS
|
112 M | $ 8.1 | -1.58 % | $ 415 M | ||
|
Evoke Pharma
EVOK
|
4.74 M | - | - | $ 36.6 M | ||
|
Harrow Health
HROW
|
72.9 M | $ 35.13 | -0.51 % | $ 1.29 B | ||
|
Jupiter Wellness
JUPW
|
2.28 M | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
104 M | - | - | $ 193 M | ||
|
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | ||
|
Organogenesis Holdings
ORGO
|
136 M | $ 2.24 | - | $ 295 M | ||
|
Pacira BioSciences
PCRX
|
277 M | $ 22.27 | -1.89 % | $ 1.03 B | ||
|
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | ||
|
Sundial Growers
SNDL
|
252 M | $ 1.34 | -1.47 % | $ 3.37 M | ||
|
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | ||
|
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
3.5 M | $ 6.9 | -1.29 % | $ 272 M | ||
|
Rockwell Medical
RMTI
|
10.7 M | $ 0.96 | 0.84 % | $ 34.5 M | ||
|
SCYNEXIS
SCYX
|
21.3 M | $ 0.92 | 3.28 % | $ 45.9 M | ||
|
Solid Biosciences
SLDB
|
59.9 M | $ 7.74 | 3.34 % | $ 677 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 2.33 | -1.9 % | $ 2.89 M | ||
|
Tilray
TLRY
|
207 M | $ 6.66 | 1.68 % | $ 4.12 B | ||
|
Veru
VERU
|
24.9 M | $ 2.4 | 4.8 % | $ 324 M | ||
|
Viatris
VTRS
|
992 M | $ 13.41 | -0.22 % | $ 16.1 B | ||
|
cbdMD
YCBD
|
2.45 M | $ 0.73 | -0.4 % | $ 3.15 M | ||
|
Zomedica Corp.
ZOM
|
9.02 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | ||
|
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
345 K | $ 0.61 | -2.94 % | $ 2.62 M | ||
|
TherapeuticsMD
TXMD
|
7.48 M | $ 2.2 | 10.0 % | $ 25.5 M |